Accelerating global drug development through successful partnering for patient benefit. Our objective is to enable our partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
PT027 an investigational fixed dose combination of budesonide & albuterol for treatment of asthma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):